The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer.

Endocrine and Metabolic Diseases Research Center School of Medicine University of Zulia Maracaibo 4004 Venezuela

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Czech Advanced Technology and Research Institute Palacký University Olomouc 779 00 Olomouc Czech Republic

Universidad Simón Bolívar Facultad de Ciencias de la Salud Barranquilla 080002 Colombia

Zobrazit více v PubMed

Campbell P.J., Getz G., Korbel J.O., Stuart J.M., Jennings J.L., Stein L.D., Perry M.D., Nahal-Bose H.K., Ouellette B.F.F., Li C.H., et al. Pan-cancer analysis of whole genomes. Nature. 2020;578:82–93. PubMed PMC

Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer Statistics for the Year 2020: An Overview. Int. J. Cancer. 2021;149:778–789. doi: 10.1002/ijc.33588. PubMed DOI

Hanahan D., Weinberg R.A. Hallmarks of Cancer: The next Generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. PubMed DOI

Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12:31–46. doi: 10.1158/2159-8290.CD-21-1059. PubMed DOI

DeBerardinis R.J., Chandel N.S. Fundamentals of Cancer Metabolism. Sci. Adv. 2016;2:e1600200. doi: 10.1126/sciadv.1600200. PubMed DOI PMC

Liberti M.V., Locasale J.W. The Warburg Effect: How Does It Benefit Cancer Cells? Trends Biochem. Sci. 2016;41:211–218. doi: 10.1016/j.tibs.2015.12.001. PubMed DOI PMC

da Silva-Diz V., Lorenzo-Sanz L., Bernat-Peguera A., Lopez-Cerda M., Muñoz P. Cancer Cell Plasticity: Impact on Tumor Progression and Therapy Response. Semin. Cancer Biol. 2018;53:48–58. doi: 10.1016/j.semcancer.2018.08.009. PubMed DOI

Kalyanaraman B. Teaching the Basics of Cancer Metabolism: Developing Antitumor Strategies by Exploiting the Differences between Normal and Cancer Cell Metabolism. Redox Biol. 2017;12:833–842. doi: 10.1016/j.redox.2017.04.018. PubMed DOI PMC

Liu C.-L., Hsu Y.-C., Lee J.-J., Chen M.-J., Lin C.-H., Huang S.-Y., Cheng S.-P. Targeting the Pentose Phosphate Pathway Increases Reactive Oxygen Species and Induces Apoptosis in Thyroid Cancer Cells. Mol. Cell. Endocrinol. 2020;499:110595. doi: 10.1016/j.mce.2019.110595. PubMed DOI

Sun H., Chen L., Cao S., Liang Y., Xu Y. Warburg Effects in Cancer and Normal Proliferating Cells: Two Tales of the Same Name. Genom. Proteom. Bioinform. 2019;17:273–286. doi: 10.1016/j.gpb.2018.12.006. PubMed DOI PMC

Koundouros N., Poulogiannis G. Reprogramming of Fatty Acid Metabolism in Cancer. Br. J. Cancer. 2020;122:4–22. doi: 10.1038/s41416-019-0650-z. PubMed DOI PMC

Liu Y., Yang C. Oncometabolites in Cancer: Current Understanding and Challenges. Cancer Res. 2021;81:2820–2823. doi: 10.1158/0008-5472.CAN-20-3730. PubMed DOI

de la Cruz-López K.G., Castro-Muñoz L.J., Reyes-Hernández D.O., García-Carrancá A., Manzo-Merino J. Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Front. Oncol. 2019;9:1143. doi: 10.3389/fonc.2019.01143. PubMed DOI PMC

Benny S., Mishra R., Manojkumar M.K., Aneesh T.P. From Warburg Effect to Reverse Warburg Effect; the New Horizons of Anti-Cancer Therapy. Med. Hypotheses. 2020;144:110216. doi: 10.1016/j.mehy.2020.110216. PubMed DOI

Jiang J., Srivastava S., Zhang J. Starve Cancer Cells of Glutamine: Break the Spell or Make a Hungry Monster? Cancers. 2019;11:804. doi: 10.3390/cancers11060804. PubMed DOI PMC

Yoo H.C., Yu Y.C., Sung Y., Han J.M. Glutamine Reliance in Cell Metabolism. Exp. Mol. Med. 2020;52:1496–1516. doi: 10.1038/s12276-020-00504-8. PubMed DOI PMC

Fernández L.P., Gómez de Cedrón M., Ramírez de Molina A. Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment. Front. Oncol. 2020;10:577420. doi: 10.3389/fonc.2020.577420. PubMed DOI PMC

Castelli S., De Falco P., Ciccarone F., Desideri E., Ciriolo M.R. Lipid Catabolism and ROS in Cancer: A Bidirectional Liaison. Cancers. 2021;13:5484. doi: 10.3390/cancers13215484. PubMed DOI PMC

Lue H., Podolak J., Kolahi K., Cheng L., Rao S., Garg D., Xue C.-H., Rantala J.K., Tyner J.W., Thornburg K.L., et al. Metabolic Reprogramming Ensures Cancer Cell Survival despite Oncogenic Signaling Blockade. Genes Dev. 2017;31:2067–2084. doi: 10.1101/gad.305292.117. PubMed DOI PMC

Sun L., Suo C., Li S.-T., Zhang H., Gao P. Metabolic Reprogramming for Cancer Cells and Their Microenvironment: Beyond the Warburg Effect. Biochim. Biophys. Acta Rev. Cancer. 2018;1870:51–66. doi: 10.1016/j.bbcan.2018.06.005. PubMed DOI

Xia L., Oyang L., Lin J., Tan S., Han Y., Wu N., Yi P., Tang L., Pan Q., Rao S., et al. The Cancer Metabolic Reprogramming and Immune Response. Mol. Cancer. 2021;20:28. doi: 10.1186/s12943-021-01316-8. PubMed DOI PMC

Li T., Tan X., Yang R., Miao Y., Zhang M., Xi Y., Guo R., Zheng M., Li B. Discovery of Novel Glyceraldehyde-3-Phosphate Dehydrogenase Inhibitor via Docking-Based Virtual Screening. Bioorg. Chem. 2020;96:103620. doi: 10.1016/j.bioorg.2020.103620. PubMed DOI

Ghanbari Movahed Z., Rastegari-Pouyani M., Mohammadi M.H., Mansouri K. Cancer Cells Change Their Glucose Metabolism to Overcome Increased ROS: One Step from Cancer Cell to Cancer Stem Cell? Biomed. Pharmacother. 2019;112:108690. doi: 10.1016/j.biopha.2019.108690. PubMed DOI

Pavlova N.N., Thompson C.B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016;23:27–47. doi: 10.1016/j.cmet.2015.12.006. PubMed DOI PMC

Sun R.C., Dukhande V.V., Zhou Z., Young L.E.A., Emanuelle S., Brainson C.F., Gentry M.S. Nuclear Glycogenolysis Modulates Histone Acetylation in Human Non-Small Cell Lung Cancers. Cell Metab. 2019;30:903–916. doi: 10.1016/j.cmet.2019.08.014. PubMed DOI PMC

Grasmann G., Smolle E., Olschewski H., Leithner K. Gluconeogenesis in Cancer Cells—Repurposing of a Starvation-Induced Metabolic Pathway? Biochim. Biophys. Acta BBA Rev. Cancer. 2019;1872:24–36. doi: 10.1016/j.bbcan.2019.05.006. PubMed DOI PMC

Vincent E.E., Sergushichev A., Griss T., Gingras M.-C., Samborska B., Ntimbane T., Coelho P.P., Blagih J., Raissi T.C., Choinière L., et al. Mitochondrial Phosphoenolpyruvate Carboxykinase Regulates Metabolic Adaptation and Enables Glucose-Independent Tumor Growth. Mol. Cell. 2015;60:195–207. doi: 10.1016/j.molcel.2015.08.013. PubMed DOI

Zhou L., Luo M., Cheng L.-J., Li R.-N., Liu B., Linghu H. Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2) Promotes the EMT of Serous Ovarian Cancer by Activating the Hexosamine Biosynthetic Pathway to Increase the Nuclear Location of β-Catenin. Pathol. Res. Pract. 2019;215:152681. doi: 10.1016/j.prp.2019.152681. PubMed DOI

Bu P., Chen K.Y., Xiang K., Johnson C., Crown S.B., Rakhilin N., Ai Y., Wang L., Xi R., Astapova I., et al. Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. Cell Metab. 2018;27:1249–1262. doi: 10.1016/j.cmet.2018.04.003. PubMed DOI PMC

Hammond G.R.V., Burke J.E. Novel Roles of Phosphoinositides in Signaling, Lipid Transport, and Disease. Curr. Opin. Cell Biol. 2020;63:57–67. doi: 10.1016/j.ceb.2019.12.007. PubMed DOI PMC

Wang J., Li Y. CD36 Tango in Cancer: Signaling Pathways and Functions. Theranostics. 2019;9:4893–4908. doi: 10.7150/thno.36037. PubMed DOI PMC

Tanase C., Enciu A.M., Codrici E., Popescu I.D., Dudau M., Dobri A.M., Pop S., Mihai S., Gheorghișan-Gălățeanu A.-A., Hinescu M.E. Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately? Int. J. Mol. Sci. 2022;23:604. doi: 10.3390/ijms23020604. PubMed DOI PMC

Hu J., Zhang L., Chen W., Shen L., Jiang J., Sun S., Chen Z. Role of Intra- and Extracellular Lipid Signals in Cancer Stemness and Potential Therapeutic Strategy. Front. Pharmacol. 2021;12:730751. doi: 10.3389/fphar.2021.730751. PubMed DOI PMC

Fhu C.W., Ali A. Fatty Acid Synthase: An Emerging Target in Cancer. Molecules. 2020;25:3935. doi: 10.3390/molecules25173935. PubMed DOI PMC

Bartolacci C., Andreani C., El-Gammal Y., Scaglioni P.P. Lipid Metabolism Regulates Oxidative Stress and Ferroptosis in RAS-Driven Cancers: A Perspective on Cancer Progression and Therapy. Front. Mol. Biosci. 2021;8:706650. doi: 10.3389/fmolb.2021.706650. PubMed DOI PMC

Casals N., Zammit V., Herrero L., Fadó R., Rodríguez-Rodríguez R., Serra D. Carnitine Palmitoyltransferase 1C: From Cognition to Cancer. Prog. Lipid Res. 2016;61:134–148. doi: 10.1016/j.plipres.2015.11.004. PubMed DOI

Parrales A., Iwakuma T. P53 as a Regulator of Lipid Metabolism in Cancer. Int. J. Mol. Sci. 2016;17:2074. doi: 10.3390/ijms17122074. PubMed DOI PMC

Bott A.J., Shen J., Tonelli C., Zhan L., Sivaram N., Jiang Y.-P., Yu X., Bhatt V., Chiles E., Zhong H., et al. Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. Cell Rep. 2019;29:1287–1298. doi: 10.1016/j.celrep.2019.09.056. PubMed DOI PMC

Vettore L., Westbrook R.L., Tennant D.A. New Aspects of Amino Acid Metabolism in Cancer. Br. J. Cancer. 2020;122:150–156. doi: 10.1038/s41416-019-0620-5. PubMed DOI PMC

Hosios A.M., Hecht V.C., Danai L.V., Johnson M.O., Rathmell J.C., Steinhauser M.L., Manalis S.R., Vander Heiden M.G. Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. Dev. Cell. 2016;36:540–549. doi: 10.1016/j.devcel.2016.02.012. PubMed DOI PMC

Kurbegovic A., Trudel M. The Master Regulators Myc and P53 Cellular Signaling and Functions in Polycystic Kidney Disease. Cell. Signal. 2020;71:109594. doi: 10.1016/j.cellsig.2020.109594. PubMed DOI

Spinelli J.B., Yoon H., Ringel A.E., Jeanfavre S., Clish C.B., Haigis M.C. Metabolic Recycling of Ammonia via Glutamate Dehydrogenase Supports Breast Cancer Biomass. Science. 2017;358:941–946. doi: 10.1126/science.aam9305. PubMed DOI PMC

Lukey M.J., Katt W.P., Cerione R.A. Targeting Amino Acid Metabolism for Cancer Therapy. Drug Discov. Today. 2017;22:796–804. doi: 10.1016/j.drudis.2016.12.003. PubMed DOI PMC

Corchado-Cobos R., García-Sancha N., Mendiburu-Eliçabe M., Gómez-Vecino A., Jiménez-Navas A., Pérez-Baena M.J., Holgado-Madruga M., Mao J.-H., Cañueto J., Castillo-Lluva S., et al. Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer. Cancers. 2022;14:322. doi: 10.3390/cancers14020322. PubMed DOI PMC

Durgan J., Florey O. Cancer Cell Cannibalism: Multiple Triggers Emerge for Entosis. Biochim. Biophys. Acta Mol. Cell Res. 2018;1865:831–841. doi: 10.1016/j.bbamcr.2018.03.004. PubMed DOI

Zhang Y., Yang H., Zhao J., Wan P., Hu Y., Lv K., Hu Y., Yang X., Ma M. Activation of MAT2A-RIP1 Signaling Axis Reprograms Monocytes in Gastric Cancer. J. Immunother. Cancer. 2021;9:e001364. doi: 10.1136/jitc-2020-001364. PubMed DOI PMC

Zhang H.-F., Klein Geltink R.I., Parker S.J., Sorensen P.H. Transsulfuration, Minor Player or Crucial for Cysteine Homeostasis in Cancer. Trends Cell Biol. 2022:S0962-8924(22)000605. doi: 10.1016/j.tcb.2022.02.009. PubMed DOI PMC

Tyrakis P.A., Yurkovich M.E., Sciacovelli M., Papachristou E.K., Bridges H.R., Gaude E., Schreiner A., D’Santos C., Hirst J., Hernandez-Fernaud J., et al. Fumarate Hydratase Loss Causes Combined Respiratory Chain Defects. Cell Rep. 2017;21:1036–1047. doi: 10.1016/j.celrep.2017.09.092. PubMed DOI PMC

Gonçalves E., Sciacovelli M., Costa A.S.H., Tran M.G.B., Johnson T.I., Machado D., Frezza C., Saez-Rodriguez J. Post-Translational Regulation of Metabolism in Fumarate Hydratase Deficient Cancer Cells. Metab. Eng. 2018;45:149–157. doi: 10.1016/j.ymben.2017.11.011. PubMed DOI PMC

Schmidt S., Gay D., Uthe F.W., Denk S., Paauwe M., Matthes N., Diefenbacher M.E., Bryson S., Warrander F.C., Erhard F., et al. A MYC–GCN2–EIF2α Negative Feedback Loop Limits Protein Synthesis to Prevent MYC-Dependent Apoptosis in Colorectal Cancer. Nat. Cell Biol. 2019;21:1413–1424. doi: 10.1038/s41556-019-0408-0. PubMed DOI PMC

Masui K., Onizuka H., Cavenee W.K., Mischel P.S., Shibata N. Metabolic Reprogramming in the Pathogenesis of Glioma: Update. Neuropathol. Off. J. Jpn. Soc. Neuropathol. 2019;39:3–13. doi: 10.1111/neup.12535. PubMed DOI

Gelman S.J., Naser F., Mahieu N.G., McKenzie L.D., Dunn G.P., Chheda M.G., Patti G.J. Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress. Cell Rep. 2018;22:512–522. doi: 10.1016/j.celrep.2017.12.050. PubMed DOI PMC

Izquierdo-Garcia J.L., Viswanath P., Eriksson P., Cai L., Radoul M., Chaumeil M.M., Blough M., Luchman H.A., Weiss S., Cairncross J.G., et al. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res. 2015;75:2999–3009. doi: 10.1158/0008-5472.CAN-15-0840. PubMed DOI PMC

Fitzpatrick S.F., Lambden S., Macias D., Puthucheary Z., Pietsch S., Mendil L., McPhail M.J.W., Johnson R.S. 2-Hydroxyglutarate Metabolism Is Altered in an In Vivo Model of LPS Induced Endotoxemia. Front. Physiol. 2020;11:1–8. doi: 10.3389/fphys.2020.00147. PubMed DOI PMC

Masisi B.K., El Ansari R., Alfarsi L., Rakha E.A., Green A.R., Craze M.L. The Role of Glutaminase in Cancer. Histopathology. 2020;76:498–508. doi: 10.1111/his.14014. PubMed DOI

Katt W.P., Lukey M.J., Cerione R.A. A Tale of Two Glutaminases: Homologous Enzymes with Distinct Roles in Tumorigenesis. Future Med. Chem. 2017;9:223–243. doi: 10.4155/fmc-2016-0190. PubMed DOI PMC

Matés J.M., Campos-Sandoval J.A., Márquez J. Glutaminase Isoenzymes in the Metabolic Therapy of Cancer. Biochim. Biophys. Acta BBA Rev. Cancer. 2018;1870:158–164. doi: 10.1016/j.bbcan.2018.07.007. PubMed DOI

Gouirand V., Guillaumond F., Vasseur S. Influence of the Tumor Microenvironment on Cancer Cells Metabolic Reprogramming. Front. Oncol. 2018;8:117. doi: 10.3389/fonc.2018.00117. PubMed DOI PMC

Robey R.B., Weisz J., Kuemmerle N., Salzberg A.C., Berg A., Brown D.G., Kubik L., Palorini R., Al-Mulla F., Al-Temaimi R., et al. Metabolic Reprogramming and Dysregulated Metabolism: Cause, Consequence and/or Enabler of Environmental Carcinogenesis? Carcinogenesis. 2015;36:S203–S231. doi: 10.1093/carcin/bgv037. PubMed DOI PMC

Anderson N.M., Simon M.C. The Tumor Microenvironment. Curr. Biol. CB. 2020;30:R921–R925. doi: 10.1016/j.cub.2020.06.081. PubMed DOI PMC

Lamouille S., Derynck R. Cell Size and Invasion in TGF-β–Induced Epithelial to Mesenchymal Transition Is Regulated by Activation of the MTOR Pathway. J. Cell Biol. 2007;178:437–451. doi: 10.1083/jcb.200611146. PubMed DOI PMC

Samarelli A.V., Masciale V., Aramini B., Coló G.P., Tonelli R., Marchioni A., Bruzzi G., Gozzi F., Andrisani D., Castaniere I., et al. Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development. Int. J. Mol. Sci. 2021;22:12179. doi: 10.3390/ijms222212179. PubMed DOI PMC

Silva V.R., Santos L.d.S., Dias R.B., Quadros C.A., Bezerra D.P. Emerging Agents That Target Signaling Pathways to Eradicate Colorectal Cancer Stem Cells. Cancer Commun. 2021;41:1275–1313. doi: 10.1002/cac2.12235. PubMed DOI PMC

Pedersen S.F., Flinck M., Pardo L.A. The Interplay between Dysregulated Ion Transport and Mitochondrial Architecture as a Dangerous Liaison in Cancer. Int. J. Mol. Sci. 2021;22:5209. doi: 10.3390/ijms22105209. PubMed DOI PMC

Su Q., Fan M., Wang J., Ullah A., Ghauri M.A., Dai B., Zhan Y., Zhang D., Zhang Y. Sanguinarine Inhibits Epithelial-Mesenchymal Transition via Targeting HIF-1α/TGF-β Feed-Forward Loop in Hepatocellular Carcinoma. Cell Death Dis. 2019;10:939. doi: 10.1038/s41419-019-2173-1. PubMed DOI PMC

Jonasch E., McCutcheon I.E., Gombos D.S., Ahrar K., Perrier N.D., Liu D., Robichaux C.C., Villarreal M.F., Weldon J.A., Woodson A.H., et al. Pazopanib in Patients with von Hippel-Lindau Disease: A Single-Arm, Single-Centre, Phase 2 Trial. Lancet Oncol. 2018;19:1351–1359. doi: 10.1016/S1470-2045(18)30487-X. PubMed DOI PMC

Zhu W., Li Y., Zhao D., Li H., Zhang W., Xu J., Hou J., Feng X., Wang H. Dihydroartemisinin Suppresses Glycolysis of LNCaP Cells by Inhibiting PI3K/AKT Pathway and Downregulating HIF-1α Expression. Life Sci. 2019;233:116730. doi: 10.1016/j.lfs.2019.116730. PubMed DOI

Hao L.-S., Liu Q., Tian C., Zhang D.-X., Wang B., Zhou D.-X., Li Z.-P., Yuan Z.-X. Correlation and Expression Analysis of Hypoxia-inducible Factor 1α, Glucose Transporter 1 and Lactate Dehydrogenase 5 in Human Gastric Cancer. Oncol. Lett. 2019;18:1431–1441. doi: 10.3892/ol.2019.10457. PubMed DOI PMC

Zhao H., Jiang H., Li Z., Zhuang Y., Liu Y., Zhou S., Xiao Y., Xie C., Zhou F., Zhou Y. 2-Methoxyestradiol Enhances Radiosensitivity in Radioresistant Melanoma MDA-MB-435R Cells by Regulating Glycolysis via HIF-1α/PDK1 Axis. Int. J. Oncol. 2017;50:1531–1540. doi: 10.3892/ijo.2017.3924. PubMed DOI PMC

Ullmann P., Qureshi-Baig K., Rodriguez F., Ginolhac A., Nonnenmacher Y., Ternes D., Weiler J., Gäbler K., Bahlawane C., Hiller K., et al. Hypoxia-Responsive MiR-210 Promotes Self-Renewal Capacity of Colon Tumor-Initiating Cells by Repressing ISCU and by Inducing Lactate Production. Oncotarget. 2016;7:65454–65470. doi: 10.18632/oncotarget.11772. PubMed DOI PMC

Gao Y., Yang F., Yang X.-A., Zhang L., Yu H., Cheng X., Xu S., Pan J., Wang K., Li P. Mitochondrial Metabolism Is Inhibited by the HIF1α-MYC-PGC-1β Axis in BRAF V600E Thyroid Cancer. FEBS J. 2019;286:1420–1436. doi: 10.1111/febs.14786. PubMed DOI

Munir R., Lisec J., Swinnen J.V., Zaidi N. Lipid Metabolism in Cancer Cells under Metabolic Stress. Br. J. Cancer. 2019;120:1090–1098. doi: 10.1038/s41416-019-0451-4. PubMed DOI PMC

van der Mijn J.C., Fu L., Khani F., Zhang T., Molina A.M., Barbieri C.E., Chen Q., Gross S.S., Gudas L.J., Nanus D.M. Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. Transl. Oncol. 2020;13:177–185. doi: 10.1016/j.tranon.2019.10.015. PubMed DOI PMC

Melone M.A.B., Valentino A., Margarucci S., Galderisi U., Giordano A., Peluso G. The Carnitine System and Cancer Metabolic Plasticity. Cell Death Dis. 2018;9:228. doi: 10.1038/s41419-018-0313-7. PubMed DOI PMC

Hashimoto N., Nagano H., Tanaka T. The Role of Tumor Suppressor P53 in Metabolism and Energy Regulation, and Its Implication in Cancer and Lifestyle-Related Diseases. Endocr. J. 2019;66:485–496. doi: 10.1507/endocrj.EJ18-0565. PubMed DOI

Moriyama H., Moriyama M., Ozawa T., Tsuruta D., Iguchi T., Tamada S., Nakatani T., Nakagawa K., Hayakawa T. Notch Signaling Enhances Stemness by Regulating Metabolic Pathways Through Modifying P53, NF-ΚB, and HIF-1α. Stem Cells Dev. 2018;27:935–947. doi: 10.1089/scd.2017.0260. PubMed DOI

Nakajima K., Kawashima I., Koshiisi M., Kumagai T., Suzuki M., Suzuki J., Mitsumori T., Kirito K. Glycolytic Enzyme Hexokinase II Is a Putative Therapeutic Target in B-Cell Malignant Lymphoma. Exp. Hematol. 2019;78:46–55. doi: 10.1016/j.exphem.2019.09.023. PubMed DOI

Lei R., Shen J., Zhang S., Liu A., Chen X., Wang Y., Sun J., Dai S., Xu J. Inactivating the Ubiquitin Ligase Parkin Suppresses Cell Proliferation and Induces Apoptosis in Human Keloids. J. Cell. Physiol. 2019;234:16601–16608. doi: 10.1002/jcp.28332. PubMed DOI

Ramos H., Calheiros J., Almeida J., Barcherini V., Santos S., Carvalho A.T.P., Santos M.M.M., Saraiva L. SLMP53-1 Inhibits Tumor Cell Growth through Regulation of Glucose Metabolism and Angiogenesis in a P53-Dependent Manner. Int. J. Mol. Sci. 2020;21:596. doi: 10.3390/ijms21020596. PubMed DOI PMC

Kim S.H., Choi S.I., Won K.Y., Lim S.-J. Distinctive Interrelation of P53 with SCO2, COX, and TIGAR in Human Gastric Cancer. Pathol. Res. Pract. 2016;212:904–910. doi: 10.1016/j.prp.2016.07.014. PubMed DOI

Liu M., Hu Y., Lu S., Lu M., Li J., Chang H., Jia H., Zhou M., Ren F., Zhong J. IC261, a Specific Inhibitor of CK1δ/ε, Promotes Aerobic Glycolysis through P53-Dependent Mechanisms in Colon Cancer. Int. J. Biol. Sci. 2020;16:882–892. doi: 10.7150/ijbs.40960. PubMed DOI PMC

Gandhi N., Das G.M. Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications. Cells. 2019;8:E89. doi: 10.3390/cells8020089. PubMed DOI PMC

He W., Xu Z., Song D., Zhang H., Li B., Gao L., Zhang Y., Feng Q., Yu D., Hu L., et al. Antitumor Effects of Rafoxanide in Diffuse Large B Cell Lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun Pathways. Life Sci. 2020;243:117249. doi: 10.1016/j.lfs.2019.117249. PubMed DOI

Zhou X., Yang X., Sun X., Xu X., Li X., Guo Y., Wang J., Li X., Yao L., Wang H., et al. Effect of PTEN Loss on Metabolic Reprogramming in Prostate Cancer Cells. Oncol. Lett. 2019;17:2856–2866. doi: 10.3892/ol.2019.9932. PubMed DOI PMC

Phadngam S., Castiglioni A., Ferraresi A., Morani F., Follo C., Isidoro C. PTEN Dephosphorylates AKT to Prevent the Expression of GLUT1 on Plasmamembrane and to Limit Glucose Consumption in Cancer Cells. Oncotarget. 2016;7:84999–85020. doi: 10.18632/oncotarget.13113. PubMed DOI PMC

Ryu M.J., Han J., Kim S.J., Lee M.J., Ju X., Lee Y.L., Son J.H., Cui J., Jang Y., Chung W., et al. PTEN/AKT Signaling Mediates Chemoresistance in Refractory Acute Myeloid Leukemia through Enhanced Glycolysis. Oncol. Rep. 2019;42:2149–2158. doi: 10.3892/or.2019.7308. PubMed DOI

Wu Q., Li Z., Liu Q. An Important Role of SREBP-1 in HBV and HCV Co-Replication Inhibition by PTEN. Virology. 2018;520:94–102. doi: 10.1016/j.virol.2018.05.011. PubMed DOI

Kachaylo E., Tschuor C., Calo N., Borgeaud N., Ungethüm U., Limani P., Piguet A.-C., Dufour J.-F., Foti M., Graf R., et al. PTEN Down-Regulation Promotes β-Oxidation to Fuel Hypertrophic Liver Growth After Hepatectomy in Mice. Hepatol. Baltim. Md. 2017;66:908–921. doi: 10.1002/hep.29226. PubMed DOI

Chen C.-Y., Chen J., He L., Stiles B.L. PTEN: Tumor Suppressor and Metabolic Regulator. Front. Endocrinol. 2018;9:338. doi: 10.3389/fendo.2018.00338. PubMed DOI PMC

Momcilovic M., Shackelford D.B. Targeting LKB1 in Cancer—Exposing and Exploiting Vulnerabilities. Br. J. Cancer. 2015;113:574–584. doi: 10.1038/bjc.2015.261. PubMed DOI PMC

Ciccarese F., Zulato E., Indraccolo S. LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective. Oxid. Med. Cell. Longev. 2019;2019:8730816. doi: 10.1155/2019/8730816. PubMed DOI PMC

Faubert B., Vincent E.E., Griss T., Samborska B., Izreig S., Svensson R.U., Mamer O.A., Avizonis D., Shackelford D.B., Shaw R.J., et al. Loss of the Tumor Suppressor LKB1 Promotes Metabolic Reprogramming of Cancer Cells via HIF-1α. Proc. Natl. Acad. Sci. USA. 2014;111:2554–2559. doi: 10.1073/pnas.1312570111. PubMed DOI PMC

Parker S.J., Svensson R.U., Divakaruni A.S., Lefebvre A.E., Murphy A.N., Shaw R.J., Metallo C.M. LKB1 Promotes Metabolic Flexibility in Response to Energy Stress. Metab. Eng. 2017;43:208–217. doi: 10.1016/j.ymben.2016.12.010. PubMed DOI PMC

Endo H., Owada S., Inagaki Y., Shida Y., Tatemichi M. Glucose Starvation Induces LKB1-AMPK-Mediated MMP-9 Expression in Cancer Cells. Sci. Rep. 2018;8:10122. doi: 10.1038/s41598-018-28074-w. PubMed DOI PMC

Cho J., Lee J., Kim J., Kim S.T., Lee S., Kim S.Y., Ha S.Y., Park C.-K., Lim H.Y. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to MTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Transl. Oncol. 2016;9:466–471. doi: 10.1016/j.tranon.2016.08.009. PubMed DOI PMC

Huynh H., Hao H.-X., Chan S.L., Chen D., Ong R., Soo K.C., Pochanard P., Yang D., Ruddy D., Liu M., et al. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to MTORC1 Inhibitor Everolimus. Mol. Cancer Ther. 2015;14:1224–1235. doi: 10.1158/1535-7163.MCT-14-0768. PubMed DOI

Jan C.-I., Tsai M.-H., Chiu C.-F., Huang Y.-P., Liu C.J., Chang N.W. Fenofibrate Suppresses Oral Tumorigenesis via Reprogramming Metabolic Processes: Potential Drug Repurposing for Oral Cancer. Int. J. Biol. Sci. 2016;12:786–798. doi: 10.7150/ijbs.13851. PubMed DOI PMC

Fan C.-S., Chen W.-S., Chen L.-L., Chen C.-C., Hsu Y.-T., Chua K.V., Wang H.-D., Huang T.-S. Osteopontin–Integrin Engagement Induces HIF-1α–TCF12-Mediated Endothelial-Mesenchymal Transition to Exacerbate Colorectal Cancer. Oncotarget. 2017;9:4998–5015. doi: 10.18632/oncotarget.23578. PubMed DOI PMC

Mossmann D., Park S., Hall M.N. MTOR Signalling and Cellular Metabolism Are Mutual Determinants in Cancer. Nat. Rev. Cancer. 2018;18:744–757. doi: 10.1038/s41568-018-0074-8. PubMed DOI

Chen J.-F., Wu P., Xia R., Yang J., Huo X.-Y., Gu D.-Y., Tang C.-J., De W., Yang F. STAT3-Induced LncRNA HAGLROS Overexpression Contributes to the Malignant Progression of Gastric Cancer Cells via MTOR Signal-Mediated Inhibition of Autophagy. Mol. Cancer. 2018;17:6. doi: 10.1186/s12943-017-0756-y. PubMed DOI PMC

Mele L., la Noce M., Paino F., Regad T., Wagner S., Liccardo D., Papaccio G., Lombardi A., Caraglia M., Tirino V., et al. Glucose-6-Phosphate Dehydrogenase Blockade Potentiates Tyrosine Kinase Inhibitor Effect on Breast Cancer Cells through Autophagy Perturbation. J. Exp. Clin. Cancer Res. CR. 2019;38:160. doi: 10.1186/s13046-019-1164-5. PubMed DOI PMC

Carroll P.A., Freie B.W., Mathsyaraja H., Eisenman R.N. The MYC Transcription Factor Network: Balancing Metabolism, Proliferation and Oncogenesis. Front. Med. 2018;12:412–425. doi: 10.1007/s11684-018-0650-z. PubMed DOI PMC

Matés J.M., Di Paola F.J., Campos-Sandoval J.A., Mazurek S., Márquez J. Therapeutic Targeting of Glutaminolysis as an Essential Strategy to Combat Cancer. Semin. Cell Dev. Biol. 2020;98:34–43. doi: 10.1016/j.semcdb.2019.05.012. PubMed DOI

Katayama R., Lovly C.M., Shaw A.T. Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015;21:2227–2235. doi: 10.1158/1078-0432.CCR-14-2791. PubMed DOI PMC

Gouw A.M., Margulis K., Liu N.S., Raman S.J., Mancuso A., Toal G.G., Tong L., Mosley A., Hsieh A.L., Sullivan D.K., et al. The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth. Cell Metab. 2019;30:556–572. doi: 10.1016/j.cmet.2019.07.012. PubMed DOI PMC

Robinson N.J., Schiemann W.P. Telomerase in Cancer: Function, Regulation, and Clinical Translation. Cancers. 2022;14:808. doi: 10.3390/cancers14030808. PubMed DOI PMC

Koh C.M., Khattar E., Leow S.C., Liu C.Y., Muller J., Ang W.X., Li Y., Franzoso G., Li S., Guccione E., et al. Telomerase Regulates MYC-Driven Oncogenesis Independent of Its Reverse Transcriptase Activity. J. Clin. Investig. 2015;125:2109–2122. doi: 10.1172/JCI79134. PubMed DOI PMC

Pupo E., Avanzato D., Middonti E., Bussolino F., Lanzetti L. KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer. Front. Oncol. 2019;9:848. doi: 10.3389/fonc.2019.00848. PubMed DOI PMC

Santana-Codina N., Roeth A.A., Zhang Y., Yang A., Mashadova O., Asara J.M., Wang X., Bronson R.T., Lyssiotis C.A., Ying H., et al. Oncogenic KRAS Supports Pancreatic Cancer through Regulation of Nucleotide Synthesis. Nat. Commun. 2018;9:4945. doi: 10.1038/s41467-018-07472-8. PubMed DOI PMC

Kimmelman A.C. Metabolic Dependencies in RAS-Driven Cancers. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015;21:1828–1834. doi: 10.1158/1078-0432.CCR-14-2425. PubMed DOI PMC

Frontiers|Macropinocytosis: A Metabolic Adaptation to Nutrient Stress in Cancer|Endocrinology. [(accessed on 24 January 2022)]. Available online: https://www.frontiersin.org/articles/10.3389/fendo.2017.00261/full. PubMed DOI PMC

Bernfeld E., Foster D.A. Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells. Trends Endocrinol. Metab. TEM. 2019;30:357–368. doi: 10.1016/j.tem.2019.03.003. PubMed DOI

Makinoshima H., Takita M., Saruwatari K., Umemura S., Obata Y., Ishii G., Matsumoto S., Sugiyama E., Ochiai A., Abe R., et al. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (MTOR) Axis Is Responsible for Aerobic Glycolysis Mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma. J. Biol. Chem. 2015;290:17495–17504. doi: 10.1074/jbc.M115.660498. PubMed DOI PMC

Min H.-Y., Lee H.-Y. Oncogene-Driven Metabolic Alterations in Cancer. Biomol. Ther. 2018;26:45–56. doi: 10.4062/biomolther.2017.211. PubMed DOI PMC

Zhang J., Song F., Zhao X., Jiang H., Wu X., Wang B., Zhou M., Tian M., Shi B., Wang H., et al. EGFR Modulates Monounsaturated Fatty Acid Synthesis through Phosphorylation of SCD1 in Lung Cancer. Mol. Cancer. 2017;16:127. doi: 10.1186/s12943-017-0704-x. PubMed DOI PMC

Ma Y., Yu C., Mohamed E.M., Shao H., Wang L., Sundaresan G., Zweit J., Idowu M., Fang X. A Causal Link from ALK to Hexokinase II Overexpression and Hyperactive Glycolysis in EML4-ALK-Positive Lung Cancer. Oncogene. 2016;35:6132–6142. doi: 10.1038/onc.2016.150. PubMed DOI PMC

Zhu H., Blake S., Kusuma F.K., Pearson R.B., Kang J., Chan K.T. Oncogene-Induced Senescence: From Biology to Therapy. Mech. Ageing Dev. 2020;187:111229. doi: 10.1016/j.mad.2020.111229. PubMed DOI

Liu X., Ding J., Meng L. Oncogene-Induced Senescence: A Double Edged Sword in Cancer. Acta Pharmacol. Sin. 2018;39:1553–1558. doi: 10.1038/aps.2017.198. PubMed DOI PMC

DeCensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., Gandini S. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis. Cancer Prev. Res. 2010;3:1451–1461. doi: 10.1158/1940-6207.CAPR-10-0157. PubMed DOI

Andronesi O.C., Arrillaga-Romany I.C., Ly K.I., Bogner W., Ratai E.M., Reitz K., Iafrate A.J., Dietrich J., Gerstner E.R., Chi A.S., et al. Pharmacodynamics of Mutant-IDH1 Inhibitors in Glioma Patients Probed by in Vivo 3D MRS Imaging of 2-Hydroxyglutarate. Nat. Commun. 2018;9:1474. doi: 10.1038/s41467-018-03905-6. PubMed DOI PMC

Basu B., Dean E., Puglisi M., Greystoke A., Ong M., Burke W., Cavallin M., Bigley G., Womack C., Harrington E.A., et al. First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clin. Cancer Res. 2015;21:3412–3419. doi: 10.1158/1078-0432.CCR-14-2422. PubMed DOI PMC

Graham L., Banda K., Torres A., Carver B.S., Chen Y., Pisano K., Shelkey G., Curley T., Scher H.I., Lotan T.L., et al. A Phase II Study of the Dual MTOR Inhibitor MLN0128 in Patients with Metastatic Castration Resistant Prostate Cancer. Investig. New Drugs. 2018;36:458–467. doi: 10.1007/s10637-018-0578-9. PubMed DOI PMC

Mueller C., Al-Batran S., Jaeger E., Schmidt B., Bausch M., Unger C., Sethuraman N. A Phase IIa Study of PEGylated Glutaminase (PEG-PGA) plus 6-Diazo-5-Oxo-L-Norleucine (DON) in Patients with Advanced Refractory Solid Tumors. J. Clin. Oncol. 2008;26:2533. doi: 10.1200/jco.2008.26.15_suppl.2533. DOI

Meric-Bernstam F., Lee R.J., Carthon B.C., Iliopoulos O., Mier J.W., Patel M.R., Tannir N.M., Owonikoko T.K., Haas N.B., Voss M.H., et al. CB-839, a Glutaminase Inhibitor, in Combination with Cabozantinib in Patients with Clear Cell and Papillary Metastatic Renal Cell Cancer (MRCC): Results of a Phase I Study. J. Clin. Oncol. 2019;37:549. doi: 10.1200/JCO.2019.37.7_suppl.549. DOI

Zhou Y., Xu Q., Shang J., Lu L., Chen G. Crocin Inhibits the Migration, Invasion, and Epithelial-mesenchymal Transition of Gastric Cancer Cells via MiR-320/KLF5/HIF-1α Signaling. J. Cell. Physiol. 2019;234:17876–17885. doi: 10.1002/jcp.28418. PubMed DOI

Liu T., Zhao L., Zhang Y., Chen W., Liu D., Hou H., Ding L., Li X. Ginsenoside 20(S)-Rg3 Targets HIF-1α to Block Hypoxia-Induced Epithelial-Mesenchymal Transition in Ovarian Cancer Cells. PLoS ONE. 2014;9:e103887. doi: 10.1371/journal.pone.0103887. PubMed DOI PMC

Düvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., Triantafellow E., Ma Q., Gorski R., Cleaver S., et al. Activation of a Metabolic Gene Regulatory Network Downstream of MTOR Complex 1. Mol. Cell. 2010;39:171–183. doi: 10.1016/j.molcel.2010.06.022. PubMed DOI PMC

Saxton R.A., Sabatini D.M. MTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168:960–976. doi: 10.1016/j.cell.2017.02.004. PubMed DOI PMC

Martini M., De Santis M.C., Braccini L., Gulluni F., Hirsch E. PI3K/AKT Signaling Pathway and Cancer: An Updated Review. Ann. Med. 2014;46:372–383. doi: 10.3109/07853890.2014.912836. PubMed DOI

Li J., Kim S.G., Blenis J. Rapamycin: One Drug, Many Effects. Cell Metab. 2014;19:373–379. doi: 10.1016/j.cmet.2014.01.001. PubMed DOI PMC

Su D.W., Mita M., Mita A.C. The Clinical Pharmacology and Toxicity Profile of Rapalogs. In: Mita M., Mita A., Rowinsky E.K., editors. mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer; Paris, France: 2016. pp. 161–189.

Meng L., Zheng X.S. Toward Rapamycin Analog (Rapalog)-Based Precision Cancer Therapy. Acta Pharmacol. Sin. 2015;36:1163–1169. doi: 10.1038/aps.2015.68. PubMed DOI PMC

Kwitkowski V.E., Prowell T.M., Ibrahim A., Farrell A.T., Justice R., Mitchell S.S., Sridhara R., Pazdur R. FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma. Oncologist. 2010;15:428–435. doi: 10.1634/theoncologist.2009-0178. PubMed DOI PMC

Jurczak W., Ramanathan S., Giri P., Romano A., Mocikova H., Clancy J., Lechuga M., Casey M., Boni J., Giza A., et al. Comparison of Two Doses of Intravenous Temsirolimus in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Leuk. Lymphoma. 2018;59:670–678. doi: 10.1080/10428194.2017.1357175. PubMed DOI

Hasskarl J. Everolimus. In: Martens U.M., editor. Small Molecules in Oncology. Volume 211. Springer International Publishing; Cham, Switzerland: 2018. pp. 101–123. Recent Results in Cancer Research.

Armstrong A.J., Shen T., Halabi S., Kemeny G., Bitting R.L., Kartcheske P., Embree E., Morris K., Winters C., Jaffe T., et al. A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer. Clin. Genitourin. Cancer. 2013;11:397–406. doi: 10.1016/j.clgc.2013.05.007. PubMed DOI

Ohtsu A., Ajani J.A., Bai Y.-X., Bang Y.-J., Chung H.-C., Pan H.-M., Sahmoud T., Shen L., Yeh K.-H., Chin K., et al. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. J. Clin. Oncol. 2013;31:3935–3943. doi: 10.1200/JCO.2012.48.3552. PubMed DOI PMC

Du L., Li X., Zhen L., Chen W., Mu L., Zhang Y., Song A. Everolimus Inhibits Breast Cancer Cell Growth through PI3K/AKT/MTOR Signaling Pathway. Mol. Med. Rep. 2018;17:7163–7169. doi: 10.3892/mmr.2018.8769. PubMed DOI PMC

Chui M.H., Kjaer S.K., Frederiksen K., Hannibal C.G., Wang T.-L., Vang R., Shih I.-M. BRAF V600E -Mutated Ovarian Serous Borderline Tumors Are at Relatively Low Risk for Progression to Serous Carcinoma. Oncotarget. 2019;10:6870–6878. doi: 10.18632/oncotarget.27326. PubMed DOI PMC

Singh J.C., Novik Y., Stein S., Volm M., Meyers M., Smith J., Omene C., Speyer J., Schneider R., Jhaveri K., et al. Phase 2 Trial of Everolimus and Carboplatin Combination in Patients with Triple Negative Metastatic Breast Cancer. Breast Cancer Res. 2014;16:3389. doi: 10.1186/bcr3634. PubMed DOI PMC

Zhang H., Dou J., Yu Y., Zhao Y., Fan Y., Cheng J., Xu X., Liu W., Guan S., Chen Z., et al. MTOR ATP-Competitive Inhibitor INK128 Inhibits Neuroblastoma Growth via Blocking MTORC Signaling. Apoptosis. 2015;20:50–62. doi: 10.1007/s10495-014-1066-0. PubMed DOI PMC

Zhang S., Song X., Cao D., Xu Z., Fan B., Che L., Hu J., Chen B., Dong M., Pilo M.G., et al. Pan-MTOR Inhibitor MLN0128 Is Effective against Intrahepatic Cholangiocarcinoma in Mice. J. Hepatol. 2017;67:1194–1203. doi: 10.1016/j.jhep.2017.07.006. PubMed DOI PMC

Voss M.H., Gordon M.S., Mita M., Rini B., Makker V., Macarulla T., Smith D.C., Cervantes A., Puzanov I., Pili R., et al. Phase 1 Study of MTORC1/2 Inhibitor Sapanisertib (TAK-228) in Advanced Solid Tumours, with an Expansion Phase in Renal, Endometrial or Bladder Cancer. Br. J. Cancer. 2020;123:1590–1598. doi: 10.1038/s41416-020-01041-x. PubMed DOI PMC

Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., Vincent J.P., Ellston R., Jones D., Sini P., et al. AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In Vitro and In Vivo Antitumor Activity. Cancer Res. 2010;70:288–298. doi: 10.1158/0008-5472.CAN-09-1751. PubMed DOI

Pike K.G., Malagu K., Hummersone M.G., Menear K.A., Duggan H.M.E., Gomez S., Martin N.M.B., Ruston L., Pass S.L., Pass M. Optimization of Potent and Selective Dual MTORC1 and MTORC2 Inhibitors: The Discovery of AZD8055 and AZD2014. Bioorg. Med. Chem. Lett. 2013;23:1212–1216. doi: 10.1016/j.bmcl.2013.01.019. PubMed DOI

Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin Passes the Torch: A New Generation of MTOR Inhibitors. Nat. Rev. Drug Discov. 2011;10:868–880. doi: 10.1038/nrd3531. PubMed DOI

Sparks C.A., Guertin D.A. Targeting MTOR: Prospects for MTOR Complex 2 Inhibitors in Cancer Therapy. Oncogene. 2010;29:3733–3744. doi: 10.1038/onc.2010.139. PubMed DOI PMC

Janes M.R., Limon J.J., So L., Chen J., Lim R.J., Chavez M.A., Vu C., Lilly M.B., Mallya S., Ong S.T., et al. Effective and Selective Targeting of Leukemia Cells Using a TORC1/2 Kinase Inhibitor. Nat. Med. 2010;16:205–213. doi: 10.1038/nm.2091. PubMed DOI PMC

Asahina H., Nokihara H., Yamamoto N., Yamada Y., Tamura Y., Honda K., Seki Y., Tanabe Y., Shimada H., Shi X., et al. Safety and Tolerability of AZD8055 in Japanese Patients with Advanced Solid Tumors; a Dose-Finding Phase I Study. Investig. New Drugs. 2013;31:677–684. doi: 10.1007/s10637-012-9860-4. PubMed DOI

Eyre T.A., Hildyard C., Hamblin A., Ali A.S., Houlton A., Hopkins L., Royston D., Linton K.M., Pettitt A., Rule S., et al. A Phase II Study to Assess the Safety and Efficacy of the Dual MTORC1/2 Inhibitor Vistusertib in Relapsed, Refractory DLBCL. Hematol. Oncol. 2019;37:352–359. doi: 10.1002/hon.2662. PubMed DOI

Slotkin E.K., Patwardhan P.P., Vasudeva S.D., de Stanchina E., Tap W.D., Schwartz G.K. MLN0128, an ATP-Competitive MTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma. Mol. Cancer Ther. 2015;14:395–406. doi: 10.1158/1535-7163.MCT-14-0711. PubMed DOI PMC

Badawi M., Kim J., Dauki A., Sutaria D., Motiwala T., Reyes R., Wani N., Kolli S., Jiang J., Coss C.C., et al. CD44 Positive and Sorafenib Insensitive Hepatocellular Carcinomas Respond to the ATP-Competitive MTOR Inhibitor INK128. Oncotarget. 2018;9:26032–26045. doi: 10.18632/oncotarget.25430. PubMed DOI PMC

Zhou H.-Y., Huang S.-L. Current Development of the Second Generation of MTOR Inhibitors as Anticancer Agents. Chin. J. Cancer. 2013;32:8–18. doi: 10.5732/cjc.011.10281. PubMed DOI PMC

Bresin A., Cristofoletti C., Caprini E., Cantonetti M., Monopoli A., Russo G., Narducci M.G. Preclinical Evidence for Targeting PI3K/MTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma. J. Investig. Dermatol. 2020;140:1045–1053. doi: 10.1016/j.jid.2019.08.454. PubMed DOI

Hu X., Xia M., Wang J., Yu H., Chai J., Zhang Z., Sun Y., Su J., Sun L. Dual PI3K/MTOR Inhibitor PKI-402 Suppresses the Growth of Ovarian Cancer Cells by Degradation of Mcl-1 through Autophagy. Biomed. Pharmacother. 2020;129:110397. doi: 10.1016/j.biopha.2020.110397. PubMed DOI

Wu Y.-Y., Wu H.-C., Wu J.-E., Huang K.-Y., Yang S.-C., Chen S.-X., Tsao C.-J., Hsu K.-F., Chen Y.-L., Hong T.-M. The Dual PI3K/MTOR Inhibitor BEZ235 Restricts the Growth of Lung Cancer Tumors Regardless of EGFR Status, as a Potent Accompanist in Combined Therapeutic Regimens. J. Exp. Clin. Cancer Res. 2019;38:282. doi: 10.1186/s13046-019-1282-0. PubMed DOI PMC

Rubinstein M.M., Hyman D.M., Caird I., Won H., Soldan K., Seier K., Iasonos A., Tew W.P., O’Cearbhaill R.E., Grisham R.N., et al. Phase 2 Study of LY3023414 in Patients with Advanced Endometrial Cancer Harboring Activating Mutations in the PI3K Pathway. Cancer. 2020;126:1274–1282. doi: 10.1002/cncr.32677. PubMed DOI PMC

Shapiro G.I., Bell-McGuinn K.M., Molina J.R., Bendell J., Spicer J., Kwak E.L., Pandya S.S., Millham R., Borzillo G., Pierce K.J., et al. First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and MTOR in Patients with Advanced Cancer. Clin. Cancer Res. 2015;21:1888–1895. doi: 10.1158/1078-0432.CCR-14-1306. PubMed DOI PMC

Bendell J.C., Varghese A.M., Hyman D.M., Bauer T.M., Pant S., Callies S., Lin J., Martinez R., Wickremsinhe E., Fink A., et al. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/MTOR Dual Inhibitor, in Patients with Advanced Cancer. Clin. Cancer Res. 2018;24:3253–3262. doi: 10.1158/1078-0432.CCR-17-3421. PubMed DOI

Salazar R., Garcia-Carbonero R., Libutti S.K., Hendifar A.E., Custodio A., Guimbaud R., Lombard-Bohas C., Ricci S., Klümpen H.-J., Capdevila J., et al. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2018;23:766-e90. doi: 10.1634/theoncologist.2017-0144. PubMed DOI PMC

Khan K.H., Wong M., Rihawi K., Bodla S., Morganstein D., Banerji U., Molife L.R. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/MTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. Oncologist. 2016;21:855–860. doi: 10.1634/theoncologist.2015-0248. PubMed DOI PMC

Wang D., Meng G., Zheng M., Zhang Y., Chen A., Wu J., Wei J. The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells. PLoS ONE. 2016;11:e0166423. doi: 10.1371/journal.pone.0166423. PubMed DOI PMC

Wang Z., Liu F., Fan N., Zhou C., Li D., Macvicar T., Dong Q., Bruns C.J., Zhao Y. Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies. Front. Oncol. 2020;10:589508. doi: 10.3389/fonc.2020.589508. PubMed DOI PMC

Li L., Meng Y., Li Z., Dai W., Xu X., Bi X., Bian J. Discovery and Development of Small Molecule Modulators Targeting Glutamine Metabolism. Eur. J. Med. Chem. 2019;163:215–242. doi: 10.1016/j.ejmech.2018.11.066. PubMed DOI

Emadi A., Jun S.A., Tsukamoto T., Fathi A.T., Minden M.D., Dang C.V. Inhibition of Glutaminase Selectively Suppresses the Growth of Primary Acute Myeloid Leukemia Cells with IDH Mutations. Exp. Hematol. 2014;42:247–251. doi: 10.1016/j.exphem.2013.12.001. PubMed DOI

Shukla K., Ferraris D.V., Thomas A.G., Stathis M., Duvall B., Delahanty G., Alt J., Rais R., Rojas C., Gao P., et al. Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-Phenylacetamido-1,2,4-Thiadiazol-2-Yl)Ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors. J. Med. Chem. 2012;55:10551–10563. doi: 10.1021/jm301191p. PubMed DOI PMC

Ren L., Ruiz-Rodado V., Dowdy T., Huang S., Issaq S.H., Beck J., Wang H., Tran Hoang C., Lita A., Larion M., et al. Glutaminase-1 (GLS1) Inhibition Limits Metastatic Progression in Osteosarcoma. Cancer Metab. 2020;8:4. doi: 10.1186/s40170-020-0209-8. PubMed DOI PMC

Earhart R.H., Amato D.J., Chang Y.-C.A., Borden E.C., Shiraki M., Dowd M.E., Comis R.L., Davis T.E., Smith T.J. Phase II Trial of 6-Diazo-5-Oxo-L-Norleucine versus Aclacinomycin-A in Advanced Sarcomas and Mesotheliomas. Investig. New Drugs. 1990;8:113–119. doi: 10.1007/BF00216936. PubMed DOI

Calithera Biosciences, Inc Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid Tumors; clinicaltrials.gov. [(accessed on 20 January 2022)];2020 Available online: https://clinicaltrials.gov/ct2/show/NCT02071862.

First-in-Human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination with Atezolizumab in Patients with Advanced Solid Tumors—No Study Results Posted—ClinicalTrials.Gov. [(accessed on 24 January 2022)]; Available online: https://clinicaltrials.gov/ct2/show/results/NCT04471415.

Hampp C., Borders-Hemphill V., Moeny D.G., Wysowski D.K. Use of Antidiabetic Drugs in the U.S., 2003–2012. Diabetes Care. 2014;37:1367–1374. doi: 10.2337/dc13-2289. PubMed DOI

Torres W., Nava M., Galbán N., Gómez Y., Morillo V., Rojas M., Cano C., Chacín M., D′Marco L., Herazo Y., et al. Anti-Aging Effect of Metformin: A Molecular and Therapeutical Perspective. Curr. Pharm. Des. 2020;26:4496–4508. doi: 10.2174/1381612826666200716161610. PubMed DOI

Shank J.J., Yang K., Ghannam J., Cabrera L., Johnston C.J., Reynolds R.K., Buckanovich R.J. Metformin Targets Ovarian Cancer Stem Cells In Vitro and In Vivo. Gynecol. Oncol. 2012;127:390–397. doi: 10.1016/j.ygyno.2012.07.115. PubMed DOI PMC

Ugwueze C.V., Ogamba O.J., Young E.E., Onyenekwe B.M., Ezeokpo B.C. Metformin: A Possible Option in Cancer Chemotherapy. Anal. Cell. Pathol. 2020;2020:7180923. doi: 10.1155/2020/7180923. PubMed DOI PMC

Evans J.M.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and Reduced Risk of Cancer in Diabetic Patients. BMJ. 2005;330:1304–1305. doi: 10.1136/bmj.38415.708634.F7. PubMed DOI PMC

Yu H., Zhong X., Gao P., Shi J., Wu Z., Guo Z., Wang Z., Song Y. The Potential Effect of Metformin on Cancer: An Umbrella Review. Front. Endocrinol. 2019;10:617. doi: 10.3389/fendo.2019.00617. PubMed DOI PMC

Franciosi M., Lucisano G., Lapice E., Strippoli G.F.M., Pellegrini F., Nicolucci A. Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review. PLoS ONE. 2013;8:e71583. doi: 10.1371/journal.pone.0071583. PubMed DOI PMC

Kasznicki J., Sliwinska A., Drzewoski J. Metformin in Cancer Prevention and Therapy. Ann. Transl. Med. 2014;2:57. doi: 10.3978/j.issn.2305-5839.2014.06.01. PubMed DOI PMC

Wu S., Zhang Q., Zhang F., Meng F., Liu S., Zhou R., Wu Q., Li X., Shen L., Huang J., et al. HER2 Recruits AKT1 to Disrupt STING Signalling and Suppress Antiviral Defence and Antitumour Immunity. Nat. Cell Biol. 2019;21:1027–1040. doi: 10.1038/s41556-019-0352-z. PubMed DOI

Sung M., Tan X., Lu B., Golas J., Hosselet C., Wang F., Tylaska L., King L., Zhou D., Dushin R., et al. Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1) Mol. Cancer Ther. 2018;17:243–253. doi: 10.1158/1535-7163.MCT-17-0403. PubMed DOI

Tian C., Yuan Z., Xu D., Ding P., Wang T., Zhang L., Jiang Z. Inhibition of Glycolysis by a Novel EGFR/HER2 Inhibitor KU004 Suppresses the Growth of HER2+ Cancer. Exp. Cell Res. 2017;357:211–221. doi: 10.1016/j.yexcr.2017.05.019. PubMed DOI

Chang J., Wang Q., Bhetuwal A., Liu W. Metabolic Pathways Underlying GATA6 Regulating Trastuzumab Resistance in Gastric Cancer Cells Based on Untargeted Metabolomics. Int. J. Med. Sci. 2020;17:3146–3164. doi: 10.7150/ijms.50563. PubMed DOI PMC

Su B., Huang T., Jin Y., Yin H., Qiu H., Yuan X. Apatinib Exhibits Synergistic Effect with Pyrotinib and Reverses Acquired Pyrotinib Resistance in HER2-Positive Gastric Cancer via Stem Cell Factor/c-Kit Signaling and Its Downstream Pathways. Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc. 2021;24:352–367. doi: 10.1007/s10120-020-01126-9. PubMed DOI PMC

Wu C.-S., Wei K.-L., Chou J.-L., Lu C.-K., Hsieh C.-C., Lin J.M.J., Deng Y.-F., Hsu W.-T., Wang H.-M.D., Leung C.-H., et al. Aberrant JAK/STAT Signaling Suppresses TFF1 and TFF2 through Epigenetic Silencing of GATA6 in Gastric Cancer. Int. J. Mol. Sci. 2016;17:E1467. doi: 10.3390/ijms17091467. PubMed DOI PMC

Liu J., Pan C., Guo L., Wu M., Guo J., Peng S., Wu Q., Zuo Q. A New Mechanism of Trastuzumab Resistance in Gastric Cancer: MACC1 Promotes the Warburg Effect via Activation of the PI3K/AKT Signaling Pathway. J. Hematol. Oncol. J. Hematol. Oncol. 2016;9:76. doi: 10.1186/s13045-016-0302-1. PubMed DOI PMC

Wang X., Du Z., Xu T., Wang X., Li W., Gao J., Li J., Zhu H. HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies. Front. Oncol. 2021;11:785111. doi: 10.3389/fonc.2021.785111. PubMed DOI PMC

Grande F., Aiello F., Garofalo A., Neamati N. Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity. Mini-Rev. Med. Chem. 2016;16:644–650. doi: 10.2174/138955751608160307175649. PubMed DOI

Lu T., Tang J., Shrestha B., Heath B.R., Hong L., Lei Y.L., Ljungman M., Neamati N. Up-Regulation of Hypoxia-Inducible Factor Antisense as a Novel Approach to Treat Ovarian Cancer. Theranostics. 2020;10:6959–6976. doi: 10.7150/thno.41792. PubMed DOI PMC

Greenberger L.M., Horak I.D., Filpula D., Sapra P., Westergaard M., Frydenlund H.F., Albæk C., Schrøder H., Ørum H. A RNA Antagonist of Hypoxia-Inducible Factor-1α, EZN-2968, Inhibits Tumor Cell Growth. Mol. Cancer Ther. 2008;7:3598–3608. doi: 10.1158/1535-7163.MCT-08-0510. PubMed DOI

Bin Y.-L., Hu H.-S., Tian F., Wen Z.-H., Yang M.-F., Wu B.-H., Wang L.-S., Yao J., Li D.-F. Metabolic Reprogramming in Gastric Cancer: Trojan Horse Effect. Front. Oncol. 2022;11:1–14. doi: 10.3389/fonc.2021.745209. PubMed DOI PMC

Lu J., Chen H., He F., You Y., Feng Z., Chen W., Li X., Zhao L. Ginsenoside 20(S)-Rg3 Upregulates HIF-1α-targeting MiR-519a-5p to Inhibit the Warburg Effect in Ovarian Cancer Cells. Clin. Exp. Pharmacol. Physiol. 2020;47:1455–1463. doi: 10.1111/1440-1681.13321. PubMed DOI

Bortner C.D., Cidlowski J.A. Ion Channels and Apoptosis in Cancer. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2014;369:20130104. doi: 10.1098/rstb.2013.0104. PubMed DOI PMC

Wulff H., Castle N.A. Therapeutic Potential of KCa3.1 Blockers: Recent Advances and Promising Trends. Expert Rev. Clin. Pharmacol. 2010;3:385–396. doi: 10.1586/ecp.10.11. PubMed DOI PMC

Sontheimer H. An Unexpected Role for Ion Channels in Brain Tumor Metastasis. Exp. Biol. Med. Maywood NJ. 2008;233:779–791. doi: 10.3181/0711-MR-308. PubMed DOI PMC

Turner K.L., Sontheimer H. Cl- and K+ Channels and Their Role in Primary Brain Tumour Biology. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2014;369:20130095. doi: 10.1098/rstb.2013.0095. PubMed DOI PMC

Mamelak A.N., Jacoby D.B. Targeted Delivery of Antitumoral Therapy to Glioma and Other Malignancies with Synthetic Chlorotoxin (TM-601) Expert Opin. Drug Deliv. 2007;4:175–186. doi: 10.1517/17425247.4.2.175. PubMed DOI

Mamelak A.N., Rosenfeld S., Bucholz R., Raubitschek A., Nabors L.B., Fiveash J.B., Shen S., Khazaeli M.B., Colcher D., Liu A., et al. Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults with Recurrent High-Grade Glioma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2006;24:3644–3650. doi: 10.1200/JCO.2005.05.4569. PubMed DOI

Hockaday D.C., Shen S., Fiveash J., Raubitschek A., Colcher D., Liu A., Alvarez V., Mamelak A.N. Imaging Glioma Extent with 131I-TM-601. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2005;46:580–586. PubMed

Zuliani V., Rapalli A., Patel M.K., Rivara M. Sodium Channel Blockers: A Patent Review (2010–2014) Expert Opin. Ther. Pat. 2015;25:279–290. doi: 10.1517/13543776.2014.995628. PubMed DOI

Djamgoz M.B.A., Onkal R. Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease. Recent Patents Anticancer Drug Discov. 2013;8:66–84. doi: 10.2174/1574892811308010066. PubMed DOI

Vandenberg J.I., Perry M.D., Perrin M.J., Mann S.A., Ke Y., Hill A.P. HERG K(+) Channels: Structure, Function, and Clinical Significance. Physiol. Rev. 2012;92:1393–1478. doi: 10.1152/physrev.00036.2011. PubMed DOI

Fnu G., Weber G.F. Alterations of Ion Homeostasis in Cancer Metastasis: Implications for Treatment. Front. Oncol. 2021;11:765329. doi: 10.3389/fonc.2021.765329. PubMed DOI PMC

Szablewski L. Glucose Transporters as Markers of Diagnosis and Prognosis in Cancer Diseases. Oncol. Rev. 2022;16:561. doi: 10.4081/oncol.2022.561. PubMed DOI PMC

Pliszka M., Szablewski L. Glucose Transporters as a Target for Anticancer Therapy. Cancers. 2021;13:4184. doi: 10.3390/cancers13164184. PubMed DOI PMC